Endocrine Abstracts

Obesity, characterized by an abnormal body fat accumulation mainly caused by a chronic imbalance between energy intake and expenditure, is a massive public health problem. Targeting excessive fat deposition in adipose tissue and ectopic fat accumulation in skeletal muscle through promoting lipid oxidation pathway may represent a promising strategy to counteract obesity. This study aims at investigating the effects of cabergoline (CAB), a dopamine agonist, on adipose and skelet...

Cushing’s disease (CD), caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor, is the most common form of hypercortisolism. Pituitary surgery is the first-line treatment of CD and medical treatment is an alternative second-line approach to control cortisol excess. Long-term exposure to glucocorticoids (GC) downregulates the expression of somatostatin receptor type 2 (SSTR2) but not type 5 (SSTR5) in human and mouse ACTH-secreting tumor cell cultures; t...

The transcriptional activator Bmal1, reaching acrophase in the morning and bathyphase in the evening, is the main regulator of circadian clock. A mutual interaction between circadian clock and glucocorticoids (GCs) has been described as well as their implication in muscle metabolism. The current in vitro study aims at investigating Bmal1 involvement in muscle catabolism induced by GCs circadian exposure. To this aim, mouse myocytes C2C12 were serum-shocked to synchron...

Acquired resistance has limited the use of systemic molecular therapy in the management of hepatocellular carcinoma (HCC). Immunotherapy, alone and in combination with systemic molecular therapy, is now the first-line standard of care for HCC. The current in vitro study aims at investigating PER2 role in the HCC aggressiveness and drug resistance acquisition. Parental PLC/PRF/5, PLC/PRF/5 resistant to Everolimus (EveR) and to Sorafenib (SorR) cell lines were used. To evaluate ...

HCC is a difficult-to-treat-cancer with poor prognosis. EVOLVE-1 trial demonstrated that EVE did not improve overall survival in molecularly and clinically unselected patients with advanced HCC resistant to sorafenib. In selected patients, the well-established antitumor effect of EVE could make this a potential adjuvant therapy. Unfortunately, EVE acquired resistance due to the tumor adaptation to chronic drug use is a current challenge. VitD was deemed as potential regimen to...